Every 10-Q that Olema Pharmaceuticals, Inc. (OLMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OLMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OLMA filings page.
Olema Pharmaceuticals, Inc., a clinical-stage oncology company, reported a larger net loss while maintaining a substantial cash position for the six months ended June 30, 2026. Total operating expenses rose to $125.2 million from $82.7 million a year earlier, driven primarily by increased research and development spending of $107.0 million and higher general and administrative costs of $18.1 million. Net loss widened to $116.3 million compared with $74.2 million in the prior-year period, or $1.12 per share versus $0.87.
The company generated $9.3 million of interest income from its investment portfolio. Cash used in operating activities was $91.9 million in the first half of 2026, partially offset by $45.4 million provided by investing activities and $46.8 million from financing, including $41.9 million of net proceeds from an at-the-market equity offering. As of June 30, 2026, Olema held $461.2 million in cash, cash equivalents and marketable securities and reported management’s view that these resources, together with available borrowing capacity, are sufficient to fund the current operating plan for at least 12 months from the reporting date.
Olema continues to advance its lead ER-targeted therapy palazestrant (OP-1250) and KAT6 inhibitor OP-3136, supported by multiple collaboration and supply agreements with Novartis and Pfizer. The company also expanded its facilities footprint with new long-term leases for future headquarters and additional office space, adding fixed lease commitments while existing short-term lease liabilities declined.
Olema Pharmaceuticals reported a larger quarterly loss as it invests heavily in cancer drug development, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss was $53.1 million compared with $30.4 million a year earlier, driven mainly by higher research and development expenses of $49.2 million and general and administrative expenses of $8.8 million.
Total assets were $530.6 million, including $505.3 million in cash, cash equivalents and marketable securities. Operating cash outflow was $46.0 million, largely offset by $41.9 million of net proceeds from an at-the-market stock program. Management believes existing cash, securities and available debt capacity will fund the current operating plan for at least 12 months. As of May 7, 2026, common shares outstanding were 87.3 million, excluding 13.6 million shares issuable upon exercise of pre-funded warrants.
Olema Pharmaceuticals (OLMA) reported Q3 2025 results, highlighting higher operating spend as its breast cancer programs advance. The company posted a net loss of $42.2 million, compared with $34.6 million a year ago. Research and development was $40.0 million and general and administrative was $5.9 million, reflecting continued clinical activity.
Liquidity remains strong, with $329.0 million in cash, cash equivalents and marketable securities at September 30, 2025, and an additional $22.0 million available under its loan facility. Stockholders’ equity was $307.5 million. The company’s weighted average share count was 85.7 million, which includes the effect of pre-funded warrants.
Olema has an at-the-market program of up to $150.0 million established in January 2025 with no sales to date. Previously, a November 2024 private placement raised $250.0 million gross (net approximately $237.0 million). As of November 5, 2025, 68,659,923 shares were outstanding; there are 17,094,163 shares issuable upon exercise of pre-funded warrants at $0.0001 per share, subject to beneficial ownership limits.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company advancing palazestrant (OP-1250) and a KAT6 inhibitor (OP-3136). At June 30, 2025 the company reported total cash, cash equivalents and marketable securities of $361.9 million (cash and cash equivalents of $52.5 million and marketable securities of $309.4 million) and an available balance of $22.0 million under its loan agreement; management states this liquidity is sufficient to fund the current operating plan for at least the next 12 months. Total assets were $382.0 million with stockholders' equity of $345.2 million.
For the quarter ended June 30, 2025, Olema recorded a net loss of $43.8 million (loss per share $0.51); for the six months the net loss was $74.2 million (loss per share $0.87). Research and development expense was $43.9 million for the quarter and $74.5 million for six months, which included a $10.0 million one-time milestone to Aurigene. The company drew $3.0 million under its Credit Facility and continues collaborations with Novartis and Pfizer to supply CDK4/6 inhibitors for clinical trials; it completed a 2024 private placement that generated approximately $237.0 million net proceeds and maintains an at-the-market program with $150.0 million capacity.